Patrys Limited (ASX:PAB)

Australia · Delayed Price · Currency is AUD

0.0340

0.00 (0.00%)

Sep 18, 2026, 3:29 PM AEST

Market Cap	22.94M +150.3%
Revenue (ttm)	8.99K -98.9%
Net Income	-3.41M
EPS	-0.01
Shares Out	674.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	207,276
Open	0.0340
Previous Close	0.0340
Day's Range	0.0340 - 0.0340
52-Week Range	0.0150 - 0.0520
Beta	1.25
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is base... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2006

Employees 10

Stock Exchange Australian Securities Exchange

Ticker Symbol PAB

Full Company Profile

Financial Performance

In fiscal year 2026, Patrys's revenue was 8,985, a decrease of -98.92% compared to the previous year's 828,540. Losses were -3.41 million, 13.3% more than in 2025.

Financial Statements